Onconova Therapeutics

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

KemPharm

Novan

Cassava Sciences Inc

Investing in biotech stocks isn't for the faint of heart, but these can be some of the most lucrative equities on the market. The post How to Pick the Best Small Cap Biotech Stocks to Buy appeared first on InvestorPlace.

How to Pick the Best Small Cap Biotech Stocks to Buy

Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 12. Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 12.

Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2021 Financial Results on August 12, 2021

Onconova Therapeutics, Inc. (ONTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Onconova Therapeutics, Inc. (ONTX) Report Negative Q2 Earnings? What You Should Know

Expansion of trial underway at highest dose in the current protocol, and continued dose escalation under consideration

Onconova Therapeutics Provides an Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer

NEWTOWN, Pa., June 22, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that on June 17, 2021 it received a letter from The Nasdaq Stock Market LLC stating that the Company has regained compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2), as the Company's common stock had a closing bid price of at least $1.00 per share for 18 consecutive business days, from May 21, 2021 to June 16, 2021.

Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement

Onconova Therapeutics, Inc. (ONTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Onconova Therapeutics, Inc. (ONTX) Upgraded to Buy: What Does It Mean for the Stock?

Phase 1 study to evaluate ON 123300 in advanced cancer patients including HR+ HER 2- metastatic breast cancer patients resistant to approved CDK 4/6 inhibitors Phase 1 study to evaluate ON 123300 in advanced cancer patients including HR+ HER 2- metastatic breast cancer patients resistant to approved CDK 4/6 inhibitors

Onconova Therapeutics Announces the Initial Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of ON 123300

Onconova Therapeutics Inc (NASDAQ: ONTX) announced a 1-for-15 reverse stock split of its common stock, effective May 20, 2021. These are the details.

Onconova Therapeutics (ONTX): 1-For-15 Reverse Stock Split

Aehr Test Systems

Immutep Ltd

Uxin Ltd - ADR

Are these the top penny stocks to buy in 2021? Take a look and decide for yourself The post Top Penny Stocks to Buy Now?

Top Penny Stocks to Buy Now? 4 Big Movers to Watch Today

NEWTOWN, Pa., May 20, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX) (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced a one-for-fifteen reverse stock split of its common stock, effective May 20, 2021. Beginning at the open of trading on May 21, 2021, Onconova's common stock will trade on the Nasdaq Capital Market on a split-adjusted basis.

Onconova Therapeutics Announces Reverse Stock Split and Decrease in Authorized Shares

The stock price of Onconova Therapeutics Inc (NASDAQ: ONTX) increased by 75.04%. This is why it happened.

Onconova Therapeutics (ONTX) Stock: 75.04% Increase Explanation

Onconova Therapeutics, Inc. (NASDAQ: ONTX) shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and $4 price target. Onconova Therapeutics is a biopharmaceutical company focused on discovering and developing novel products to treat cancer.

Why Onconova Therapeutic's Is Surging Today

AcelRx Pharmaceuticals

Agenus

Biotech penny stocks continue to heat up; here's 4 under $5 to look into The post Biotech Penny Stocks Are On Fire Today, Here's 3 to Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Biotech Penny Stocks Are On Fire Today, Here's 3 to Watch Under $5

The stock price of Onconova Therapeutics Inc (NASDAQ: ONTX) increased by over 30% pre-market. This is why it happened.

Onconova Therapeutics (ONTX) Stock: Over 30% Increase Pre-Market Explanation

Onconova Therapeutics, Inc. (ONTX) CEO Steven Fruchtman on Q1 2021 Results - Earnings Call Transcript

Conference call and live webcast at 4:30 p.m. ET today

Onconova Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

Aerpio Pharmaceuticals Inc

Ideanomics Inc

These penny stocks moved big in early morning trading; here's why The post Penny Stocks to Buy in May 2021? Here's 3 Big Pre-Market Gainers appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks to Buy in May 2021? Here's 3 Big Pre-Market Gainers

Aikido Pharma Inc.

Actinium Pharmaceuticals

Atossa Genetics

Bionano Genomics

CTI BioPharma

These seven risky Reddit penny stocks are in the biotech space and the business of developing cancer therapies and treatments. The post 7 Reddit Penny Stocks Promising to Cure Cancer appeared first on InvestorPlace.

7 Reddit Penny Stocks Promising to Cure Cancer

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Monday, May 17. Company to host conference call and webcast at 4:30 p.m. Eastern Time on Monday, May 17.

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2021 Financial Results on May 17, 2021

Onconova Therapeutics, Inc. (ONTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Asensus Surgical

Iterum Therapeutics Plc

Zomedica

Biotech penny stocks continue to see momentum; should you add these 3 to your watchlist? The post Top Biotech Penny Stocks to Buy?

Top Biotech Penny Stocks to Buy? 4 Biotech Stocks to Watch Before May 2021

Corporate Partner HanX Biopharmaceuticals enrolled third patient in 80 mg group Corporate Partner HanX Biopharmaceuticals enrolled third patient in 80 mg group

Onconova Therapeutics Announces Enrollment in Second Cohort of Phase 1 Study with ON 123300 in China

NEWTOWN, Pa., March 29, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President and Chief Executive Officer, will present a Company overview and hold one-on-one meetings during the Spring 2021 Oncology Investor Conference, sponsored by the National Foundation for Cancer Research.

Onconova to Present at the Spring 2021 Oncology Investor Conference

Onconova's targeted anti-cancer agents enhance the bull thesis for ONTX stock, but the stock's volatile price action raises a red flag. The post Be Cautious as Onconova Therapeutics Stock Flirts With De-Listing appeared first on InvestorPlace.

Be Cautious as Onconova Therapeutics Stock Flirts With De-Listing

American Resources Corp

Lipocine

Tonix Pharmaceuticals Hld

Zhongchao

Amid risk-on sentiment, penny stocks are surging higher today as investors seek to grab the higher upside these small-cap stocks provide. The post Top Penny Stocks News Today: TNXP, ONTX, AREC, LPCN and ZCMD appeared first on InvestorPlace.

Top Penny Stocks News Today: TNXP, ONTX, AREC, LPCN and ZCMD

News for Onconova Therapeutics Stock (ONTX)